Status:

COMPLETED

Intracorporeal Nanocomposites and Neurological Disorders in Fulgurates (FulgurnanoF)

Lead Sponsor:

University Hospital, Clermont-Ferrand

Collaborating Sponsors:

PROMES UPR 8521 DR2-CNRS

LPC UMR 6533, Campus Universitaire des Cézeaux

Conditions:

Neurologic Disorder

Eligibility:

All Genders

7-80 years

Brief Summary

Objective: To demonstrate the presence of bioresistant intracorporeal carbon-based nanocomposites in subjects exposed to a fulguration, in the immediate aftermath of this fulguration and 24 months (+/...

Detailed Description

In order to detect nanocomposites in patients who have been impacted by lightning, an analysis protocol will be performed on the remains of blood and urine samples from their initial medical admission...

Eligibility Criteria

Inclusion

  • Inclusion criteria :
  • Patients exposed: all subjects who were victims of the fulguration accident.
  • Non-exposed patients:
  • 14 subjects,
  • of all ages,
  • free of major pathology and having never been the victim of a fulguration accident, nor having witnessed a fulguration at less than 20 meters,
  • having never worked in a high-energy environment (CEA, EDF, particle accelerator, AREVA-type laboratory, radiology manipulator, radiation protection profession).
  • Exclusion criteria :
  • Pregnant or breastfeeding woman.
  • Subject under guardianship, curatorship or safeguard of justice, or deprived of liberties.
  • Any condition judged by the investigator to be incompatible with the research.
  • Refusal to participate. Exposed patients: if the above-mentioned accident induced more than a simple lightning strike (lightning: died by lightning, electrocution: touched by an electric current, electrocution: died by contact with an electric current).

Exclusion

    Key Trial Info

    Start Date :

    May 20 2019

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 10 2020

    Estimated Enrollment :

    27 Patients enrolled

    Trial Details

    Trial ID

    NCT04380194

    Start Date

    May 20 2019

    End Date

    September 10 2020

    Last Update

    September 11 2020

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    CH Henri Mondor

    Aurillac, France

    2

    CH de Luneville

    Lunéville, France

    3

    CHRU Bradois

    Nancy, France

    4

    CHRU de Nancy

    Nancy, France